Hormone therapy and risk of myocardial infarction: a national register study.
about
HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRTUpdated clinical recommendations for the use of tibolone in Asian womenThe 2012 hormone therapy position statement of: The North American Menopause Society.Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study.Vascular effects of estrogenic menopausal hormone therapy.Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort studyThe effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors.Age-related changes in dorsal root ganglia, circulating and vascular calcitonin gene-related peptide (CGRP) concentrations in female rats: effect of female sex steroid hormonesType and route of estrogen administration.Reviewing the options for local estrogen treatment of vaginal atrophy.Drugs for the treatment of menopausal symptoms.Transdermal menopausal hormone therapy: delivery through skin changes the rules.Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.Systematic review of cardiovascular disease in women: assessing the risk.Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.Menopausal hormone therapy: examining cardiovascular and clinical impacts of treatment.Postmenopausal hormone therapy and coronary heart disease in early postmenopausal women.Benefits and risks during HRT: main safety issue breast cancer.Safety and benefit considerations for menopausal hormone therapy.Attitude of German gynecologists towards prescribing HRT before and after the WHI study.Vaginal estradiol use and the risk for cardiovascular mortality.Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators.Natural hormone therapy for menopause.Is There a Role for Menopausal Hormone Therapy (MHT) for Cardiovascular Disease Prevention in Select Postmenopausal Women?Principles of drug literature evaluation for observational study designs.Hormone therapy and risk of myocardial infarction.Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
P2860
Q28294446-673FE5CE-1169-438E-9E51-3C3B3B91318CQ34142418-21FC3D75-FBF7-4FB2-AC43-925EF7DA0F82Q34161400-474D4380-C90A-4EA1-A966-7F925207AF90Q34375771-A38E6F1C-342A-4619-B074-4E0C121A13B3Q34476118-40700644-C37C-4261-AD0D-D66E6741E4CEQ35583311-F3645B64-51BC-4DC1-BD9B-78BC1A7B7634Q35856372-2390C9F4-111E-4AB7-9EE0-409075E89326Q37218944-C6F7ECAF-4A1C-40FB-A448-B37D06B5B801Q37291507-06C58BC7-9498-49BA-B39F-9F8461E0E2AEQ37434573-BAD46D1C-CC47-48FB-B277-20C3B5347B62Q37610402-AF6E2E62-1EF0-403C-815C-15825F541FEFQ37644593-B1362486-20C7-43B6-81FF-A6FBF0B2E0C2Q37735189-7A6F31BD-46F2-4DD6-9D40-4519B6D96E98Q37738900-5BC22A8C-CD4B-4DB6-86EA-E57BE7A36A6BQ37768413-9FB0C1FF-559A-4545-AE3B-4AA9A7ECF160Q37954418-D44F07B2-071B-4662-8898-058097CF757EQ37995321-E4578EBA-0D80-46FE-BCC3-7AD3CFD4C1E0Q38106504-551336ED-94BC-4D41-9CA6-9CC77B24EBB0Q38165230-C647EDA8-6741-4D96-86E1-77DA1B0CCDD4Q38471535-0B2A0A6D-8271-4188-8C41-0BF18096A736Q38700757-5065E617-939F-4941-A03E-055083497291Q39254200-E2D83D04-DE7F-4FF4-A6FE-525EC86559DEQ39999161-2420CA3B-14AA-40FD-80FC-EF99C68408FDQ43063161-475BB729-6542-4D02-8FDE-56A9E6D440C3Q43227534-A5CE6F6D-2BBC-4911-B3E8-F47025C516E1Q44592446-7B21230C-E97D-4491-9887-876C4A7C2527Q45236376-543C1BBA-99EC-4BC8-B639-ABB9CCB604C5Q46186398-D052ED99-62F1-49EE-AF06-77F90337ADAEQ52879856-8DE70D89-8F39-4DE9-9075-81FC1273BA23Q55060038-80A38EE2-9ADC-4D3F-B376-1F59FBC23204Q58362346-CAB22F04-D777-46BC-B489-E3F986B0FEDD
P2860
Hormone therapy and risk of myocardial infarction: a national register study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Hormone therapy and risk of myocardial infarction: a national register study.
@en
Hormone therapy and risk of myocardial infarction: a national register study.
@nl
type
label
Hormone therapy and risk of myocardial infarction: a national register study.
@en
Hormone therapy and risk of myocardial infarction: a national register study.
@nl
prefLabel
Hormone therapy and risk of myocardial infarction: a national register study.
@en
Hormone therapy and risk of myocardial infarction: a national register study.
@nl
P2093
P50
P356
P1476
Hormone therapy and risk of myocardial infarction: a national register study.
@en
P2093
Carsten Agger
Lars Hougaard Nielsen
Øjvind Lidegaard
P304
P356
10.1093/EURHEARTJ/EHN408
P577
2008-09-30T00:00:00Z